Paper42985516PubMed
Antigen-specific regulatory cell therapy approaches in kidney transplantation.
Tripathi S and 1 other. Front Immunol, 2026.
Cite this record
ConductScience Library. Antigen-specific regulatory cell therapy approaches in kidney transplantation. Papers, record 42985516. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/42985516
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Antigen-specific regulatory cell therapy approaches in kidney transplantation.
- Journal
- Front Immunol
- Year
- 2026
- Publication types
- Journal Article, Review
- Revised in PubMed
- 2026-11-06
Source PubMed
Topics9
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Kidney Transplantation | Major topic |
| T-Lymphocytes, Regulatory | Major topic |
| Graft Rejection | Major topic |
| Immunotherapy, Adoptive | Major topic |
| Humans | |
| Animals | |
| Transplantation Tolerance | |
| Isoantigens | |
| Graft Survival |
Source PubMed
References54
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 33519807 | The Therapeutic Potential of Regulatory T Cells: Challenges and Opportunities. | Front Immunol | 2020 | https://conductscience.org/library/papers/33519807 | PubMed |
| 2 | 35694562 | Study Design: Human Leukocyte Antigen Class I Molecule A∗02-Chimeric Antigen Receptor Regulatory T Cells in Renal Transplantation. | Kidney Int Rep | 2022 | https://conductscience.org/library/papers/35694562 | PubMed |
| 3 | 22167587 | Regulatory T cells in kidney transplant recipients: the effect of induction immunosuppression therapy. | Nephrol Dial Transplant | 2012 | https://conductscience.org/library/papers/22167587 | PubMed |
| 4 | 29552576 | A Rapamycin-Based GMP-Compatible Process for the Isolation and Expansion of Regulatory T Cells for Clinical Trials. | Mol Ther Methods Clin Dev | 2018 | https://conductscience.org/library/papers/29552576 | PubMed |
| 5 | 33087345 | Regulatory T cells for minimising immune suppression in kidney transplantation: phase I/IIa clinical trial. | BMJ | 2020 | https://conductscience.org/library/papers/33087345 | PubMed |
| 6 | 42358982 | CD25+CD27+CD70- alloantigen-specific Tregs: promising stable immunotherapy for transplantation. | Front Immunol | 2026 | https://conductscience.org/library/papers/42358982 | PubMed |
| 7 | 39824564 | Optimizing protocols for human regulatory T isolation, expansion, and characterization. | Methods Cell Biol | 2025 | https://conductscience.org/library/papers/39824564 | PubMed |
| 8 | 35371066 | Adenosinergic Pathway and Linked Suppression: Two Critical Suppressive Mechanisms of Human Donor Antigen Specific Regulatory T Cell Lines Expanded Post Transplant. | Front Immunol | 2022 | https://conductscience.org/library/papers/35371066 | PubMed |
| 9 | 26773713 | A pilot study of operational tolerance with a regulatory T-cell-based cell therapy in living donor liver transplantation. | Hepatology | 2016 | https://conductscience.org/library/papers/26773713 | PubMed |
| 10 | 27693388 | Clinical-grade regulatory T cells: Comparative analysis of large-scale expansion conditions. | Exp Hematol | 2017 | https://conductscience.org/library/papers/27693388 | PubMed |
| 11 | 22566933 | Molecular mechanisms of treg-mediated T cell suppression. | Front Immunol | 2012 | https://conductscience.org/library/papers/22566933 | PubMed |
| 12 | 37422112 | Donor antigen-specific regulatory T cell administration to recipients of live donor kidneys: A ONE Study consortium pilot trial. | Am J Transplant | 2023 | https://conductscience.org/library/papers/37422112 | PubMed |
| 13 | 30429370 | Early expansion of donor-specific Tregs in tolerant kidney transplant recipients. | JCI Insight | 2018 | https://conductscience.org/library/papers/30429370 | PubMed |
| 14 | 36972454 | Tonic-signaling chimeric antigen receptors drive human regulatory T cell exhaustion. | Proc Natl Acad Sci U S A | 2023 | https://conductscience.org/library/papers/36972454 | PubMed |
| 15 | 35434896 | Anti-HLA-A2-CAR Tregs prolong vascularized mouse heterotopic heart allograft survival. | Am J Transplant | 2022 | https://conductscience.org/library/papers/35434896 | PubMed |
| 16 | 40740779 | Navigating the manufacturing, testing and regulatory complexities of regulatory T cells for adoptive cell therapy. | Front Immunol | 2025 | https://conductscience.org/library/papers/40740779 | PubMed |
| 17 | 29743501 | A Phase I Clinical Trial with Ex Vivo Expanded Recipient Regulatory T cells in Living Donor Kidney Transplants. | Sci Rep | 2018 | https://conductscience.org/library/papers/29743501 | PubMed |
| 18 | 31811270 | Treg cell-based therapies: challenges and perspectives. | Nat Rev Immunol | 2020 | https://conductscience.org/library/papers/31811270 | PubMed |
| 19 | 34705520 | Alloantigen-specific type 1 regulatory T cells suppress through CTLA-4 and PD-1 pathways and persist long-term in patients. | Sci Transl Med | 2021 | https://conductscience.org/library/papers/34705520 | PubMed |
| 20 | 41246323 | Regulatory T cell therapies: from patient data to biological insights. | Front Immunol | 2025 | https://conductscience.org/library/papers/41246323 | PubMed |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- Cited by
- Genes
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/42985516
GET https://conductscience.org/api/papers/v1/42985516/references?page=2